6 beta-Hydroxycortisol excretion in hypercortisolemic states. 1979

E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New

Urinary 6beta-hydroxycortisol (6betaOHF) excretion was measured and compared with free cortisol and 17-hydroxycorticosteroid (17OH) excretion in normal children, patients with Cushing's syndrome or disease (CSD), and patients during cortisol therapy. Normal 6betaOHF excretion in children was 0.23 +/- 0.03 mg/m2/24 h (mean +/- SE). No sex difference was found. ACTH infusion (40 U/day for 5 days) and high dose cortisol altered the 6 betaOHF:17OH ratio so that it was indistinguishable from the ratio seen in CSD. The fact that both Cushing's disease and high dose cortisol therapy caused the same change in the 6 betaOHF:17OH ratio suggests that cortisol and not ACTH induced 6beta-hydroxylase in hypercortisolemic subjects. Since the 6betaOHF:17OH ratio in CSD patients was always well above the normal range, measurement of 6betaOHF excretion was a better and more rapid test for chronic hypercortisolemia than urinary 17OH or free cortisol. Thus, measurement of urinary 6betaOHF is suggested as a good diagnostic test for hypercortisolemic states.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015065 17-Hydroxycorticosteroids A group of hydroxycorticosteroids bearing a hydroxy group at the 17-position. Urinary excretion of these compounds is used as an index of adrenal function. They are used systemically in the free alcohol form, but with esterification of the hydroxy groups, topical effectiveness is increased. 17 Hydroxycorticosteroids

Related Publications

E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
September 1982, Journal of steroid biochemistry,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
June 1969, The Journal of clinical endocrinology and metabolism,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
January 1997, British journal of rheumatology,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
February 1984, The Journal of clinical endocrinology and metabolism,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
August 1967, Horumon to rinsho. Clinical endocrinology,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
May 1998, Clinical and experimental pharmacology & physiology,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
May 1982, British journal of clinical pharmacology,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
E Voccia, and P Saenger, and R E Peterson, and W Rauh, and K Gottesdiener, and L S Levine, and M I New
April 1969, Steroids,
Copied contents to your clipboard!